Active, not recruitingPhase 2NCT04042753
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
Studying Pituitary carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Andrew Lin, MDMemorial Sloan Kettering Cancer Center
- Intervention
- Ipilimumab(drug)
- Enrollment
- 9 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2026
Study locations (8)
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04042753 on ClinicalTrials.gov